DK2970132T3 - Argininmethyltransferaseinhibitorer og anvendelser deraf - Google Patents

Argininmethyltransferaseinhibitorer og anvendelser deraf Download PDF

Info

Publication number
DK2970132T3
DK2970132T3 DK14717371.0T DK14717371T DK2970132T3 DK 2970132 T3 DK2970132 T3 DK 2970132T3 DK 14717371 T DK14717371 T DK 14717371T DK 2970132 T3 DK2970132 T3 DK 2970132T3
Authority
DK
Denmark
Prior art keywords
methyltransferase inhibitors
arginine methyltransferase
arginine
inhibitors
methyltransferase
Prior art date
Application number
DK14717371.0T
Other languages
Danish (da)
English (en)
Inventor
Richard Chesworth
Lorna Helen Mitchell
Gideon Shapiro
Keren Kalai Swinger
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Application granted granted Critical
Publication of DK2970132T3 publication Critical patent/DK2970132T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14717371.0T 2013-03-14 2014-03-14 Argininmethyltransferaseinhibitorer og anvendelser deraf DK2970132T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781051P 2013-03-14 2013-03-14
US201361876034P 2013-09-10 2013-09-10
PCT/US2014/029710 WO2014153226A1 (en) 2013-03-14 2014-03-14 Arginine methyltransferase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
DK2970132T3 true DK2970132T3 (da) 2020-12-21

Family

ID=50483598

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14717371.0T DK2970132T3 (da) 2013-03-14 2014-03-14 Argininmethyltransferaseinhibitorer og anvendelser deraf

Country Status (24)

Country Link
US (5) US9598374B2 (enExample)
EP (1) EP2970132B1 (enExample)
JP (1) JP6581076B2 (enExample)
KR (2) KR102028793B1 (enExample)
CN (2) CN105339351B (enExample)
AU (2) AU2014236146B2 (enExample)
BR (1) BR112015022785A2 (enExample)
CA (1) CA2903394C (enExample)
CY (1) CY1123637T1 (enExample)
DK (1) DK2970132T3 (enExample)
EA (1) EA030481B1 (enExample)
ES (1) ES2837034T3 (enExample)
HR (1) HRP20202008T1 (enExample)
HU (1) HUE052926T2 (enExample)
IL (2) IL241368B (enExample)
LT (1) LT2970132T (enExample)
MX (1) MX382991B (enExample)
PL (1) PL2970132T3 (enExample)
PT (1) PT2970132T (enExample)
RS (1) RS61231B1 (enExample)
SG (1) SG11201506972PA (enExample)
SI (1) SI2970132T1 (enExample)
WO (1) WO2014153226A1 (enExample)
ZA (1) ZA201507441B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US10118918B2 (en) 2012-12-21 2018-11-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CA2903394C (en) * 2013-03-14 2021-08-31 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム，インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
WO2014144169A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Carm1 inhibitors and uses thereof
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2016044576A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
CN110225983A (zh) * 2016-12-01 2019-09-10 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的方法
WO2018100532A1 (en) * 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
EP3548069A1 (en) * 2016-12-01 2019-10-09 GlaxoSmithKline Intellectual Property Development Limited Combination therapy
BR112020017541A2 (pt) 2018-03-01 2020-12-22 Board Of Regents, The University Of Texas System Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt
CA3101561A1 (en) * 2018-05-31 2019-12-05 Glaxosmithkline Intellectual Property Development Limited Combined therapy with icos binding proteins and argininemethyltransferase inhibitors
WO2020182018A1 (zh) * 2019-03-12 2020-09-17 四川科伦博泰生物医药股份有限公司 氮杂环化合物、其制备方法及用途
EP3947387B1 (en) * 2019-03-25 2024-10-23 California Institute Of Technology Prmt5 inhibitors and uses thereof
WO2021023609A1 (en) * 2019-08-02 2021-02-11 Glaxosmithkline Intellectual Property Development Limited Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor
CN110950841A (zh) * 2019-11-22 2020-04-03 济南大学 一类新型三唑类化合物的合成及应用
KR102219251B1 (ko) 2020-03-03 2021-02-22 김명수 전문가 추천 플랫폼을 제공하는 서버 및 그 운용방법
CN111481532B (zh) * 2020-06-28 2020-09-22 南京中澳转化医学研究院有限公司 化合物28d在制备提高γ-珠蛋白表达量的药物中的应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085859B2 (ja) 1986-07-01 1996-01-24 日本バイエルアグロケム株式会社 新規アルキレンジアミン類
US5204482A (en) 1988-07-28 1993-04-20 Hoffman-Laroche Inc. Compounds for treating and preventing cognitive diseases and depression and methods of making same
EP0352581A3 (de) 1988-07-28 1990-07-04 F. Hoffmann-La Roche Ag Aethylendiaminmonoamid-Derivate
AU3993795A (en) 1994-12-02 1996-06-19 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds for prevention and/or treatment of no-mediated diseases
SE9902765D0 (sv) 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
CN1331326A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸
US20020090627A1 (en) 2000-10-05 2002-07-11 Rachel Meyers 27419, a novel human arginine-N-methyl transferase and uses thereof
DE10149370A1 (de) 2001-10-06 2003-04-10 Merck Patent Gmbh Pyrazolderivate
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
DE10315572A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
WO2004098634A2 (en) 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
US20050032794A1 (en) 2003-08-05 2005-02-10 Padia Janak K. Diamine derivatives of quinone and uses thereof
DE102004008807A1 (de) 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
KR101166342B1 (ko) 2004-03-15 2012-07-18 얀센 파마슈티카 엔.브이. 아편계 약물 수용체 조절자로서의 신규의 화합물
CA2577937C (en) 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
DE602004023766D1 (de) 2004-08-31 2009-12-03 Univ North Carolina Dot1-histon-methyltransferasen als ziel zur identifizierung von therapeutika gegen leukämie
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
EP1802600A1 (en) 2004-10-13 2007-07-04 Bayer HealthCare AG Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonits for the treatment of urological disorders
US9550990B2 (en) 2004-12-10 2017-01-24 Ionis Pharmaceuticals, Inc. Regulation of epigenetic control of gene expression
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
EP1845973B1 (en) 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
US20060235037A1 (en) * 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
MX2008001778A (es) 2005-08-19 2008-04-07 Aventis Pharma Inc Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
WO2007091393A1 (ja) 2006-02-07 2007-08-16 Taisho Pharmaceutical Co., Ltd. １０ａ－アザライド化合物
US20090306201A1 (en) 2006-06-23 2009-12-10 University Of Medicine And Dentistry Of New Jersey Selective inhibitors for transferases
WO2008001076A1 (en) 2006-06-26 2008-01-03 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
US20090253673A1 (en) 2006-07-12 2009-10-08 Min Ge Substituted Pyrazoles as Ghrelin Receptor Antagonists
JP2010503656A (ja) 2006-09-13 2010-02-04 アストラゼネカ アクチボラグ スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用
US8648096B2 (en) 2006-09-15 2014-02-11 Celgene Corporation N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
US20080312298A1 (en) 2007-04-11 2008-12-18 Kenneth William Foreman Methods for Identification of Modulators of Carm1 Methyl Transferase Activity
WO2008137834A2 (en) 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US8133904B2 (en) 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2009084695A1 (ja) 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体
JP2009179616A (ja) 2008-01-31 2009-08-13 Kowa Co ３−ナフチルピラゾール化合物
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
WO2009126537A1 (en) 2008-04-07 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an hmt inhibitor
JP5764822B2 (ja) 2008-08-27 2015-08-19 オンコセラピー・サイエンス株式会社 がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
TWI607996B (zh) 2008-09-24 2017-12-11 巴地斯顏料化工廠 控制無脊椎害蟲之吡唑化合物
US8323918B2 (en) 2008-12-12 2012-12-04 University Of South Carolina Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases
US20130345268A1 (en) 2009-02-13 2013-12-26 The Trustees Of Dartmouth College Methods and Compositions for the Treatment of RAS Associated Disorders
WO2010094009A2 (en) 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders
EP2221053A1 (de) 2009-02-20 2010-08-25 Albert-Ludwigs-Universität Freiburg Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen
RU2011141121A (ru) * 2009-03-11 2013-04-20 Окленд Юнисервисиз Лимитед Пролекарственные формы ингибиторов киназ и их применение в терапии
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011011366A2 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
WO2011082098A1 (en) 2009-12-30 2011-07-07 The Rockefeller University Lysine and arginine methyltransferase inhibitors for treating cancer
WO2011096210A1 (en) 2010-02-03 2011-08-11 Oncotherapy Science, Inc. Prmt1 and prmt6 for target genes of cancer therapy and diagnosis
EP2531598A4 (en) 2010-02-03 2013-05-22 Oncotherapy Science Inc WHSC1 AND WHSC1L1 FOR TARGET GENES TO CANCER THERAPY AND DIAGNOSIS
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
WO2012060760A1 (en) 2010-11-05 2012-05-10 Fujirebio Diagnostics Ab Molecular marker for cancer
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
US9394310B2 (en) 2010-12-03 2016-07-19 Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
CN103391939B (zh) 2010-12-03 2016-03-09 Epizyme股份有限公司 作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
UY34997A (es) 2012-08-30 2014-03-31 Nihon Nohyaku Co Ltd Agente de control de endoparásitos y método para usarlo
CN106963760A (zh) 2012-08-30 2017-07-21 国立大学法人东京大学 体内寄生虫防治剂在制备防治体内寄生虫的药物中的用途
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
WO2014100764A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Methods of inhibiting prmt5
US10118918B2 (en) 2012-12-21 2018-11-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム，インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
CA2903394C (en) * 2013-03-14 2021-08-31 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014144169A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Carm1 inhibitors and uses thereof
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US20170280720A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044576A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
WO2016044604A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
US20170283400A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
US20170298073A1 (en) 2014-09-17 2017-10-19 Epizyme, Inc Salts, co-crystals, amorphous forms, and crystalline forms of a co-activator-associated arginine methyltransferase 1 (carm1) inhibitor
WO2016044626A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044650A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
WO2017136699A1 (en) 2016-02-05 2017-08-10 Epizyme, Inc Arginine methyltransferase inhibitors and uses thereof
US20190083482A1 (en) 2017-09-18 2019-03-21 Epizyme, Inc. Prmt5 inhibitors and uses thereof

Also Published As

Publication number Publication date
HK1219736A1 (zh) 2017-04-13
CA2903394A1 (en) 2014-09-25
KR102028793B1 (ko) 2019-10-07
JP2016516067A (ja) 2016-06-02
HUE052926T2 (hu) 2021-05-28
US20190100496A1 (en) 2019-04-04
EA201591531A1 (ru) 2016-02-29
IL268189A (en) 2019-09-26
WO2014153226A9 (en) 2015-01-08
US20240182426A1 (en) 2024-06-06
US10800743B2 (en) 2020-10-13
AU2014236146B2 (en) 2018-05-17
JP6581076B2 (ja) 2019-09-25
SI2970132T1 (sl) 2021-02-26
CN105339351A (zh) 2016-02-17
MX382991B (es) 2025-03-13
US20170267642A1 (en) 2017-09-21
AU2018203056A1 (en) 2018-07-19
CN105339351B (zh) 2018-11-06
IL241368A0 (en) 2015-11-30
CY1123637T1 (el) 2022-03-24
WO2014153226A1 (en) 2014-09-25
US11512053B2 (en) 2022-11-29
PL2970132T3 (pl) 2021-04-06
IL241368B (en) 2019-07-31
AU2014236146A1 (en) 2015-09-10
RS61231B1 (sr) 2021-01-29
CN109265400B (zh) 2022-10-04
AU2018203056B2 (en) 2020-05-21
US10081603B2 (en) 2018-09-25
US20160024016A1 (en) 2016-01-28
PT2970132T (pt) 2020-12-30
IL268189B (en) 2022-02-01
KR20190112334A (ko) 2019-10-04
EP2970132B1 (en) 2020-09-23
CA2903394C (en) 2021-08-31
LT2970132T (lt) 2021-01-11
ZA201507441B (en) 2021-01-27
HRP20202008T1 (hr) 2021-02-19
US20210078951A1 (en) 2021-03-18
ES2837034T3 (es) 2021-06-29
US9598374B2 (en) 2017-03-21
SG11201506972PA (en) 2015-10-29
KR102158756B1 (ko) 2020-09-23
MX2015012850A (es) 2016-06-24
EP2970132A1 (en) 2016-01-20
CN109265400A (zh) 2019-01-25
KR20160003648A (ko) 2016-01-11
EA030481B1 (ru) 2018-08-31
BR112015022785A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
IL268189B (en) Arginine methyltransferase inhibitors and their uses
IL267681B (en) Selective grp94 inhibitors and uses thereof
IL271580B (en) Vaporization device systems and methods
DK3043784T3 (da) Arylethere og anvendelser deraf
LT3290407T (lt) Bromodomeno inhibitoriai
IL241370A0 (en) Carm1 inhibitors and their uses
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
HUE036600T2 (hu) ERK inhibitorok és alkalmazási eljárások
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
PT2970211T (pt) Inibidores de histona demetilase
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
PL3030519T3 (pl) Trójpierścieniowe związki benzoksaborolu i ich zastosowania
DK3060200T3 (da) Tyrosinderivater og sammensætninger dermed
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
HRP20181291T1 (hr) Heterobicikloarilni inhibitori rorc2 i njihova upotreba
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
DK2941268T3 (da) Selektive nox-1-inhibitor-peptider og anvendelser deraf
BR302013005862S1 (pt) Configuração aplicada em coador
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder
EP3051144A4 (en) COMPRESSORS AND CHARGERS